Artificial intelligence (AI) has the potential to transform drug discovery, as it is reshaping other areas of science and technology. However, to exploit its full potential, we need to incorporate both biology and chemistry, and format it in a way that is amenable for modern machine learning.
This BioMed conference will explore potential strategies to bridge the gap between biological big data, drug screening experiments and state-of-the-art generative AI tools. We will also discuss how generative AI can be used to explore the uncharted chemical space and to design new chemical compounds (NCEs) with specific pharmacological properties. Indeed, deep learning strategies have successfully designed NCEs with desired anticancer activities or new antibiotic scaffolds, and 15 ML-designed drugs are already in clinical trials.
The final goal of this BioMed conference is to pave the way for the transition from precision to personalised medicine where, instead of looking for the most suitable approved drug to treat a patient, we will design specific drugs for each molecular profile.
There is no registration fee for this conference, but the number of participants is limited, with a number of seats saved for IRB Barcelona alumni. Previous registration is required.
Priority will be given to those who submit the highest quality abstracts for short talks or posters and the order of registration will be considered.
Abstracts should include a title, authors, affiliations, summary (max 250 words) and references
REGISTRATION DEADLINE: 10 FEBRUARY, 2025
Note: For any issues with the registration or abstract, please contact: meritxell.gavalda@irbbarcelona.org
The full programme, updates, and registration can be found here.
